Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBloomsbury Regulatory News (BMY)

Share Price Information for Bloomsbury (BMY)

Share Price is delayed by 15 minutes
Get Live Data
631.00    -3.00 (-0.47%)
Bid:
631.00
Ask:
634.00
Spread: 3.00 (0.475%)
Market Cap: £510.12m
BMY Live PriceLast checked at - London Stock Exchange

Intraday Bloomsbury Share Chart

Board Appointment

22 Oct 2010 07:00

RNS Number : 8231U
Bloomsbury Publishing PLC
22 October 2010
 



 

 

Bloomsbury Publishing Plc

("Bloomsbury" or "the Company")

 

Appointment of Ian Cormack as Non-Executive Director

 

Bloomsbury Publishing Plc is pleased to announce that it has approved the appointment of Ian Cormack as a non-executive director. He will join the Board on 1st January 2011 and will also become the Senior Independent Director and Chair of the Audit Committee with effect from 1 January 2011.

 

Ian Cormack will replace Mike Mayer who will step down from the Board on 31st December 2010 after 9 years, in accordance with the UK Corporate Governance Code, of distinquished service to the Board of Bloomsbury.

 

Ian Cormack has had a successful City career in leading international and UK roles at AIG, Citigroup and Citibank, where he spent over thirty years. A former member of the Chancellor's City Advisory Panel, he has served on committees for the London Stock Exchange, CHAPS, APACS, the European Securities Forum, Cedel and the Bank of England.

He is currently Chairman of Maven Income & Company VCT4 plc and a Director of several other organisations including the Qatar Financial Centre, with whom Bloomsbury has a trading relationship, Phoenix Group Holdings, Aspen Bermuda, National Angels Ltd. Ian Cormack is also an active member of the Development Council for the National Theatre and the Campaign Committee of Pembroke College, Oxford.

 

There is no other information required to be disclosed pursuant to LR9.6.13R.

 

Commenting on the appointment Jeremy Wilson, Chairman of Bloomsbury said, "We are delighted to welcome Ian Cormack to the Board. He has a wealth of relevant experience to bring to the Board from his career and my fellow Directors and I look forward to working with him in the years to come. We will miss Mike Mayer's invaluable contribution. The Board has benefited for almost a decade from his astute counsel, guidance and support. I would like to thank him personally, on behalf of the Board and the entire Company, for all that he has done.

 

Enquiries:

 

Rosanne Perry / Dan de Belder

Pelham Bell Pottinger

020 7861 3232 or e-mail ddebelder@pelhambellpottinger.co.uk

 

About Bloomsbury Publishing Plc 

(www.bloomsbury.com and www.bloomsbury-ir.co.uk)

 

Bloomsbury Publishing is one of the world's leading independent publicly quoted publishing houses with a valuable collection of intellectual properties including QFinance: The Ultimate Resource, Encarta World English Dictionary, Wisden Cricketers' Almanack, Arden Shakespeare and Who's Who. The highly talented portfolio of authors currently includes JK Rowling, Elizabeth Gilbert, Howard Jacobson, Ben MacIntyre, Khaled Hosseini, Neal Gaiman and Margaret Atwood. 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAZMMZGNMFGGZM
Date   Source Headline
15th Apr 20257:00 amRNSAppointment of Joint Corporate Broker
20th Mar 20257:00 amRNSTrading Update and Board Appointment
3rd Mar 20257:00 amRNSNotice of Trading Update
24th Feb 20254:27 pmRNSHolding(s) in Company
14th Feb 202510:05 amRNSBLOCK LISTING SIX MONTHLY RETURN
24th Jan 20257:00 amRNSBloomsbury reaches new agreement with Amazon
16th Dec 202410:05 amRNSHolding(s) in Company
16th Dec 20249:55 amRNSHolding(s) in Company - Replacement
11th Dec 202410:24 amRNSDirector/PDMR Shareholding
9th Dec 20249:18 amRNSDirector/PDMR Shareholding
26th Nov 202411:44 amRNSHolding(s) in Company
26th Nov 202410:35 amRNSDirector/PDMR Shareholding
24th Oct 20247:00 amRNSUnaudited Interim Results
30th Sep 20247:00 amRNSNotice of Interim Results
2nd Sep 202411:31 amRNSDirector/PDMR Shareholding
29th Aug 20247:00 amRNSDirector/PDMR Shareholding
28th Aug 202410:57 amRNSDirector/PDMR Shareholding
16th Aug 20244:18 pmRNSAMENDMENT: BLOCK LISTING SIX MONTHLY RETURN
16th Aug 20249:42 amRNSBLOCK LISTING SIX MONTHLY RETURN
7th Aug 20245:36 pmRNSAwards under the 2023 Executive Share Plan
16th Jul 20243:41 pmRNSResults of the 2024 Annual General Meeting
16th Jul 20247:00 amRNSAGM Trading Update
14th Jun 20245:01 pmRNSAnnual Financial Report
14th Jun 20241:48 pmRNSBoard Appointment
29th May 20247:00 amRNSAcquisition
23rd May 20247:00 amRNSChairman Succession Announcement
23rd May 20247:00 amRNSAudited Preliminary Results
20th May 20247:00 amRNSInvestor Presentation
16th Feb 20247:00 amRNSBLOCK LISTING SIX MONTHLY RETURN
14th Feb 20247:00 amRNSTrading Update
1st Feb 20243:11 pmRNSBloomsbury launches latest Sarah J. Maas novel
15th Jan 20247:00 amRNSBloomsbury Appoints Head of Investor Relations
12th Jan 202411:45 amRNSHolding(s) in Company
9th Jan 20244:10 pmRNSDirector/PDMR Shareholding
7th Dec 20237:00 amRNSTrading Update
15th Nov 20237:00 amRNSBlocklisting Application
31st Oct 20237:00 amRNSInvestor Presentation
26th Oct 20237:00 amRNSUnaudited Interim Results
9th Oct 20231:00 pmRNSBloomsbury playwright Jon Fosse wins Nobel Prize
22nd Sep 20231:26 pmRNSDirector/PDMR Shareholdings - Correction
14th Sep 20237:00 amRNSBloomsbury launches new book by Katherine Rundell
5th Sep 20237:00 amRNSDirector/PDMR Shareholding
1st Sep 20232:05 pmRNSDirector/PDMR Shareholding
30th Aug 20231:56 pmRNSDirector/PDMR Shareholding
29th Aug 20232:11 pmRNSDirector/PDMR Shareholding
23rd Aug 20237:00 amRNSHolding(s) in Company
22nd Aug 20238:00 amRNSBloomsbury enjoys bestseller success
17th Aug 20234:40 pmRNSBLOCK LISTING SIX MONTHLY RETURN
18th Jul 20235:13 pmRNSResults of the 2023 Annual General Meeting
18th Jul 20237:00 amRNSAGM Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.